Relapsed/Refractory Mantle Cell Lymphoma
7 clinical trials · Condition
◉ Watch Relapsed/Refractory Mantle Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (NCT04880434) | Kite, A Gilead Company | 2021-04-23 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies (NCT03886831) | Prelude Therapeutics | 2019-02-11 |
| Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) (NCT02601313) | Kite, A Gilead Company | 2015-11-09 |
| A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma (NCT02460276) | Lund University Hospital | 2015-04-01 |
| Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT01838434) | Alliance for Clinical Trials in Oncology | 2013-10-17 |
Track Relapsed/Refractory Mantle Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.